PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares, rose in value on Friday, 05/13/22, with the stock price up by 11.41% to the previous day’s close as strong demand from buyers drove the stock to $35.64.
Actively observing the price movement in the last trading, the stock closed the session at $31.99, falling within a range of $31.52 and $36.82. Referring to stock’s 52-week performance, its high was $47.73, and the low was $15.38. On the whole, PRCT has fluctuated by -9.20% over the past month.
With the market capitalization of PROCEPT BioRobotics Corporation currently standing at about $1.56 billion, investors are eagerly awaiting this quarter’s results, scheduled for Nov 04, 2021. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.38, which is expected to increase to -$0.32 for fiscal year -$2.88 and then to about -$1.65 by fiscal year 2022.
Analysts have estimated the company’s revenue for the quarter at $8.7 million, with a low estimate of $8.6 million and a high estimate of $8.8 million.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days.
4 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 3 recommend it as a Buy and 0 called the PRCT stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PRCT currently trading nearly 1.36% and 8.19% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.72, while the 7-day volatility ratio is showing 12.29% which for the 30-day chart, stands at 9.19%. Furthermore, PROCEPT BioRobotics Corporation (PRCT)’s average true range (ATR) is 3.19. The company’s stock has been forecasted to trade at an average price of $43.25 over the course of the next 52 weeks, with a low of $36.00 and a high of $50.00. Based on these price targets, the low is -1.01% off current price, whereas the price has to move -40.29% to reach the yearly target high. Additionally, analysts’ median price of $43.50 is likely to be welcomed by investors because it represents a decrease of -22.05% from the current levels.
In comparison, AbbVie Inc. (ABBV) has moved lower at -0.51% on the day and was up 31.84% over the past 12 months. On the other hand, the price of Merck & Co. Inc. (MRK) has fallen -0.46% on the day. The stock, however, is off 21.11% from where it was a year ago. Additionally, there is a gain of 2.00% for GlaxoSmithKline plc (GSK) in last trading while the stock has seen an overall depriciation of 10.85%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) indicates that the trading volumes over the past 3 months, they’ve averaged 321.46K. According to company’s latest data on outstanding shares, there are 43.47 million shares outstanding.
Nearly 1.00% of PROCEPT BioRobotics Corporation’s shares belong to company insiders and institutional investors own 62.70% of the company’s shares. The stock has risen by 42.50% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRCT stock heading into the next quarter.